| Identification | Back Directory | [Name]
ZGN-1061 | [CAS]
2082752-83-6 | [Synonyms]
ZGN-1061
Aclimostat
1-Azetidinecarboxylic acid, 3-[2-(4-morpholinyl)ethyl]-, (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester | [Molecular Formula]
C26H42N2O6 | [MDL Number]
MFCD34589886 | [MOL File]
2082752-83-6.mol | [Molecular Weight]
478.62 |
| Chemical Properties | Back Directory | [Boiling point ]
571.8±50.0 °C(Predicted) | [density ]
1.20±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
7.42±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells[1]. | [References]
[1] Burkey BF, Hoglen NC, Inskeep P, Wyman M, Hughes TE, Vath JE. Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061. J Pharmacol Exp Ther. 2018 May;365(2):301-313. DOI:10.1124/jpet.117.246272 |
|
|